Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company’s goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.
相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂停
1
50.0%
Unknown
1
50.0%
暂无批准数据